CFM
ANRO icon

Cornerstone Financial Management’s Alto Neuroscience ANRO Stock Holding History

Cornerstone Financial Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55K Hold
69
– – ﹤0.01% 822
2025
Q4 		$1.23K Buy
+69
New +$869 ﹤0.01% 845

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cornerstone Financial Management's ANRO Position: Q1 2026 in Review

Cornerstone Financial Management held its Alto Neuroscience (ANRO) position steady in Q1 2026 at 69 shares worth $1.55K. The position accounts for ﹤0.01% of the portfolio, ranked #822.

Cornerstone Financial Management first reported a position in ANRO in Q4 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Cornerstone Financial Management held 69 shares of Alto Neuroscience worth $1.55K as of Q1 2026.
  • Cornerstone Financial Management left its Alto Neuroscience share count unchanged in Q1 2026.
  • Alto Neuroscience made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q1 2026, its #822 holding.
  • Cornerstone Financial Management first reported a position in Alto Neuroscience in Q4 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Cornerstone Financial Management's 13F filing for Q1 2026, filed 8 May 2026.